Literature DB >> 3547944

Thalidomide induction of bone marrow transplantation tolerance.

G B Vogelsang, A D Hess, G Gordon, R Brundrette, G W Santos.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1987        PMID： 3547944

Source DB:  PubMed          Journal:  Transplant Proc        ISSN： 0041-1345            Impact factor:   1.066


× No keyword cloud information.
  7 in total

1.  Binding of thalidomide to alpha1-acid glycoprotein may be involved in its inhibition of tumor necrosis factor alpha production.

Authors:  B E Turk; H Jiang; J O Liu
Journal:  Proc Natl Acad Sci U S A       Date:  1996-07-23       Impact factor: 11.205

Review 2.  Thalidomide and derivatives: immunological investigations of tumour necrosis factor-alpha (TNF-alpha) inhibition suggest drugs capable of selective gene regulation.

Authors:  S M McHugh; T L Rowland
Journal:  Clin Exp Immunol       Date:  1997-11       Impact factor: 4.330

Review 3.  Thalidomide in human immunodeficiency virus (HIV) patients. A review of safety considerations.

Authors:  V Günzler
Journal:  Drug Saf       Date:  1992 Mar-Apr       Impact factor: 5.606

4.  Thalidomide derivatives and the immune system. I. Changes in the pattern of integrin receptors and other surface markers on T lymphocyte subpopulations of marmoset blood.

Authors:  R Neubert; A C Nogueira; D Neubert
Journal:  Arch Toxicol       Date:  1993       Impact factor: 5.153

5.  The immunosuppressive drug thalidomide induces T helper cell type 2 (Th2) and concomitantly inhibits Th1 cytokine production in mitogen- and antigen-stimulated human peripheral blood mononuclear cell cultures.

Authors:  S M McHugh; I R Rifkin; J Deighton; A B Wilson; P J Lachmann; C M Lockwood; P W Ewan
Journal:  Clin Exp Immunol       Date:  1995-02       Impact factor: 4.330

6.  Thalidomide costimulates primary human T lymphocytes, preferentially inducing proliferation, cytokine production, and cytotoxic responses in the CD8+ subset.

Authors:  P A Haslett; L G Corral; M Albert; G Kaplan
Journal:  J Exp Med       Date:  1998-06-01       Impact factor: 14.307

Review 7.  The potential use of thalidomide in the therapy of graft-versus-host disease--a review of clinical and laboratory information.

Authors:  P M Wood; S J Proctor
Journal:  Leuk Res       Date:  1990       Impact factor: 3.156
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.